The authors hypothesized that the cytokine storm described in COVID-19 patients may lead to consistent cell-based tissue factor (TF)-mediated activation of coagulation, procoagulant microvesicles (MVs) release, and massive platelet activation. COVID-19 patients have higher levels of TF+ platelets, TF+ granulocytes, and TF+ MVs than healthy subjects and coronary artery disease patients. Plasma MV-associated thrombin generation is present in prophylactic anticoagulated patients. A sustained platelet activation in terms of P-selectin expression and platelet-leukocyte aggregate formation, and altered nitric oxide/prostacyclin synthesis are also observed. COVID-19 plasma, added to the blood of healthy subjects, induces platelet activation similar to that observed invivo. This effect was blunted by pre-incubation with tocilizumab, aspirin, or a P2Y12 inhibitor.
Platelet and Endothelial Activation as Potential Mechanisms Behind the Thrombotic Complications of COVID-19 Patients / P. Canzano, M. Brambilla, B. Porro, N. Cosentino, E. Tortorici, S. Vicini, P. Poggio, A. Cascella, M.F. Pengo, F. Veglia, S. Fiorelli, A. Bonomi, V. Cavalca, D. Trabattoni, D. Andreini, E. Omodeo Salè, G. Parati, E. Tremoli, M. Camera. - In: JACC. BASIC TO TRANSLATIONAL SCIENCE. - ISSN 2452-302X. - 6:3(2021 Mar), pp. 202-218.
|Titolo:||Platelet and Endothelial Activation as Potential Mechanisms Behind the Thrombotic Complications of COVID-19 Patients|
CANZANO, PAOLA (Primo)
CAMERA, MARINA (Ultimo) (Corresponding)
|Parole Chiave:||ADP, adenosine diphosphate; CAD, coronary artery disease; COVID-19; COVID-19, coronavirus disease-2019; CRP, C-reactive protein; GPA, granulocyte–platelet aggregates; HS, healthy subject; IL, interleukin; IL-6; IL-6R, interleukin-6 receptor; LMWH, low-molecular-weight heparin; MPA, monocyte–platelet aggregates; MV, microvesicle; NO, nitric oxide; NOS, nitric oxide synthase; PGI2, prostacyclin; PLA, platelet–leukocyte aggregates; PS, phosphatidylserine; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2; TF, tissue factor; antiplatelet drugs; circulating microvesicles; platelet activation; tissue factor|
|Settore Scientifico Disciplinare:||Settore MED/11 - Malattie dell'Apparato Cardiovascolare|
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
Settore BIO/14 - Farmacologia
Settore BIO/10 - Biochimica
|Data di pubblicazione:||mar-2021|
|Data ahead of print / Data di stampa:||24-feb-2021|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.jacbts.2020.12.009|
|Appare nelle tipologie:||01 - Articolo su periodico|